Kavitha Saravanakumar

Kavitha Saravanakumar

Auto-generated profile, based on publicly available information

Kavitha Saravanakumar

Centre for Students Welfare, Tamil Nadu Agricultural University, Coimbatore 641 003, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
BGBen Glampson
Ben Glampson
JBJames Brittain
James Brittain
AKAmit Kaura
Amit Kaura
AMAbdulrahim Mulla
Abdulrahim Mulla
LMLuca Mercuri
Luca Mercuri
EMErik K Mayer
Erik K Mayer
Background: On March 11, 2020, the World Health Organization declared SARS-CoV-2, causing COVID-19, as a pandemic. The UK mass vaccination program commenced on December 8, 2020, vaccinating groups of the population deemed to be most vulnerable to severe COVID-19 infection. Objective: This study aims to assess the early vaccine administration coverage and outcome data across an integrated care system in North West London, leveraging a unique population-level care data set. Vaccine effectiveness of a single dose of the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were compared. Methods: A retrospective cohort study identified 2,183,939 individuals eligible for COVID-19 vaccination between December 8, 2020, and February 24, 2021, within a primary, secondary, and community care integrated care data set. These data were used to assess vaccination hesitancy across ethnicity, gender, and socioeconomic deprivation measures (Pearson product-moment correlations); investigate COVID-19 transmission related to vaccination hubs; and assess the early effectiveness of COVID-19 vaccination (after a single dose) using time-to-event analyses with multivariable Cox regression analysis to investigate if vaccination independently predicted positive SARS-CoV-2 in those vaccinated compared to those unvaccinated. Results: In this study, 5.88% (24,332/413,919) of individuals declined and did not receive a vaccination. Black or Black British individuals had the highest rate of declining a vaccine at 16.14% (4337/26,870). There was a strong negative association between socioeconomic deprivation and rate of declining vaccination (r=–0.94; P=.002) with 13.5% (1980/14,571) of individuals declining vaccination in the most deprived areas compared to 0.98% (869/9609) in the least. In the first 6 days after vaccination, 344 of 389,587 (0.09%) individuals tested positive for SARS-CoV-2. The rate increased to 0.13% (525/389,243) between days 7 and 13, before then gradually falling week on week. At 28 days post vaccination, there was a 74% (hazard ratio 0.26, 95% CI 0.19-0.35) and 78% (hazard ratio 0.22, 95% CI 0.18-0.27) reduction in risk of testing positive for SARS-CoV-2 for individuals that received the Oxford/AstraZeneca and Pfizer/BioNTech vaccines, respectively, when compared with unvaccinated individuals. A very low proportion of hospital admissions were seen in vaccinated individuals who tested positive for SARS-CoV-2 (288/389,587, 0.07% of all patients vaccinated) providing evidence for vaccination effectiveness after a single dose. Conclusions: There was no definitive evidence to suggest COVID-19 was transmitted as a result of vaccination hubs during the vaccine administration rollout in North West London, and the risk of contracting COVID-19 or becoming hospitalized after vaccination has been demonstrated to be low in the vaccinated population. This study provides further evidence that a single dose of either the Pfizer/BioNTech vaccine or the Oxford/AstraZeneca vaccine is effective at reducing the risk of testing positive for COVID-19 up to 60 days across all age groups, ethnic groups, and risk categories in an urban UK population.

25 May 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
AEAna Belen Espinosa-Gonzalez
Ana Belen Espinosa-Gonzalez
ANAna Luisa Neves
Ana Luisa Neves
FFFrancesca Fiorentino
Francesca Fiorentino
DPDenys Prociuk
Denys Prociuk
LHLaiba Husain
Laiba Husain
BDBrendan C Delaney
Brendan C Delaney
Background: During the pandemic, remote consultations have become the norm for assessing patients with signs and symptoms of COVID-19 to decrease the risk of transmission. This has intensified the clinical uncertainty already experienced by primary care clinicians when assessing patients with suspected COVID-19 and has prompted the use of risk prediction scores, such as the National Early Warning Score (NEWS2), to assess severity and guide treatment. However, the risk prediction tools available have not been validated in a community setting and are not designed to capture the idiosyncrasies of COVID-19 infection. Objective: The objective of this study is to produce a multivariate risk prediction tool, RECAP-V1 (Remote COVID-19 Assessment in Primary Care), to support primary care clinicians in the identification of those patients with COVID-19 that are at higher risk of deterioration and facilitate the early escalation of their treatment with the aim of improving patient outcomes. Methods: The study follows a prospective cohort observational design, whereby patients presenting in primary care with signs and symptoms suggestive of COVID-19 will be followed and their data linked to hospital outcomes (hospital admission and death). Data collection will be carried out by primary care clinicians in four arms: North West London Clinical Commissioning Groups (NWL CCGs), Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), Covid Clinical Assessment Service (CCAS), and South East London CCGs (Doctaly platform). The study involves the use of an electronic template that incorporates a list of items (known as RECAP-V0) thought to be associated with disease outcome according to previous qualitative work. Data collected will be linked to patient outcomes in highly secure environments. We will then use multivariate logistic regression analyses for model development and validation. Results: Recruitment of participants started in October 2020. Initially, only the NWL CCGs and RCGP RSC arms were active. As of March 24, 2021, we have recruited a combined sample of 3827 participants in these two arms. CCAS and Doctaly joined the study in February 2021, with CCAS starting the recruitment process on March 15, 2021. The first part of the analysis (RECAP-V1 model development) is planned to start in April 2021 using the first half of the NWL CCGs and RCGP RSC combined data set. Posteriorly, the model will be validated with the rest of the NWL CCGs and RCGP RSC data as well as the CCAS and Doctaly data sets. The study was approved by the Research Ethics Committee on May 27, 2020 (Integrated Research Application System number: 283024, Research Ethics Committee reference number: 20/NW/0266) and badged as National Institute of Health Research Urgent Public Health Study on October 14, 2020. Conclusions: We believe the validated RECAP-V1 early warning score will be a valuable tool for the assessment of severity in patients with suspected COVID-19 in the community, either in face-to-face or remote consultations, and will facilitate the timely escalation of treatment with the potential to improve patient outcomes. Trial Registration: ISRCTN registry ISRCTN13953727; https://www.isrctn.com/ISRCTN13953727 International Registered Report Identifier (IRRID): DERR1-10.2196/29072

10 January 2025 in Plant Science Today
Verified
Journal Article
Open access
PDF file
KVK Vigneshwaran
K Vigneshwaran
SLS Lakshmi
S Lakshmi
CVC Vanitha
C Vanitha
TAT Anand
T Anand
BVBabu Rajendra Prasad Venugopal
Babu Rajendra Prasad Venugopal
KNK N Nelson
K N Nelson
Abiotic stresses such as drought, salinity, high temperatures and heavy metal toxicity significantly reduce crop yield and threaten global food security. Seed biopriming is an eco-friendly and sustainable pre-sowing strategy that enhances plant resilience to these environmental challenges. It involves the use of beneficial microorganisms to colonize seeds, triggering physiological, biochemical and molecular adaptations. Biopriming enhances seed germination, seedling vigour, root architecture and improves nutrient uptake by activating stress-responsive signalling pathways, antioxidant defence mechanisms, accumulation of osmolytes and production of secondary metabolites and plant hormones such as cytokinins and indole-3-acetic acid (IAA). Additionally, it promotes systemic resistance, leading to improved growth of plants and survival under adverse conditions. Compared to other priming methods, biopriming offers long- term benefits by establishing beneficial microbial associations that support plant health throughout the growth cycle. This review highlights the microbial agents used for biopriming, mechanism of action, benefits and current research trends of seed biopriming as a sustainable approach to mitigate abiotic stress in agriculture. Understanding and optimizing this approach can significantly contribute to sustainable agricultural practices by reducing reliance on chemical inputs, thereby preventing environmental hazards, ensuring food safety and mitigating the effects of climate change.

5 May 2021 in JMIR Preprints
Verified
Preprint
Open access
BGBen Glampson
Ben Glampson
JBJames Brittain
James Brittain
AKAmit Kaura
Amit Kaura
AMAbdulrahim Mulla
Abdulrahim Mulla
LMLuca Mercuri
Luca Mercuri
EMErik K Mayer
Erik K Mayer
BACKGROUND On March 11, 2020, the World Health Organization declared SARS-CoV-2, causing COVID-19, as a pandemic. The UK mass vaccination program commenced on December 8, 2020, vaccinating groups of the population deemed to be most vulnerable to severe COVID-19 infection. OBJECTIVE This study aims to assess the early vaccine administration coverage and outcome data across an integrated care system in North West London, leveraging a unique population-level care data set. Vaccine effectiveness of a single dose of the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were compared. METHODS A retrospective cohort study identified 2,183,939 individuals eligible for COVID-19 vaccination between December 8, 2020, and February 24, 2021, within a primary, secondary, and community care integrated care data set. These data were used to assess vaccination hesitancy across ethnicity, gender, and socioeconomic deprivation measures (Pearson product-moment correlations); investigate COVID-19 transmission related to vaccination hubs; and assess the early effectiveness of COVID-19 vaccination (after a single dose) using time-to-event analyses with multivariable Cox regression analysis to investigate if vaccination independently predicted positive SARS-CoV-2 in those vaccinated compared to those unvaccinated. RESULTS In this study, 5.88% (24,332/413,919) of individuals declined and did not receive a vaccination. Black or Black British individuals had the highest rate of declining a vaccine at 16.14% (4337/26,870). There was a strong negative association between socioeconomic deprivation and rate of declining vaccination (r=–0.94; P=.002) with 13.5% (1980/14,571) of individuals declining vaccination in the most deprived areas compared to 0.98% (869/9609) in the least. In the first 6 days after vaccination, 344 of 389,587 (0.09%) individuals tested positive for SARS-CoV-2. The rate increased to 0.13% (525/389,243) between days 7 and 13, before then gradually falling week on week. At 28 days post vaccination, there was a 74% (hazard ratio 0.26, 95% CI 0.19-0.35) and 78% (hazard ratio 0.22, 95% CI 0.18-0.27) reduction in risk of testing positive for SARS-CoV-2 for individuals that received the Oxford/AstraZeneca and Pfizer/BioNTech vaccines, respectively, when compared with unvaccinated individuals. A very low proportion of hospital admissions were seen in vaccinated individuals who tested positive for SARS-CoV-2 (288/389,587, 0.07% of all patients vaccinated) providing evidence for vaccination effectiveness after a single dose. CONCLUSIONS There was no definitive evidence to suggest COVID-19 was transmitted as a result of vaccination hubs during the vaccine administration rollout in North West London, and the risk of contracting COVID-19 or becoming hospitalized after vaccination has been demonstrated to be low in the vaccinated population. This study provides further evidence that a single dose of either the Pfizer/BioNTech vaccine or the Oxford/AstraZeneca vaccine is effective at reducing the risk of testing positive for COVID-19 up to 60 days across all age groups, ethnic groups, and risk categories in an urban UK population.

5 October 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
FFFrancesca Fiorentino
Francesca Fiorentino
DPDenys Prociuk
Denys Prociuk
AEAna Belen Espinosa-Gonzalez
Ana Belen Espinosa-Gonzalez
ANAna Luisa Neves
Ana Luisa Neves
LHLaiba Husain
Laiba Husain
BDBrendan C Delaney
Brendan C Delaney
Background: Since the start of the COVID-19 pandemic, efforts have been made to develop early warning risk scores to help clinicians decide which patient is likely to deteriorate and require hospitalization. The RECAP (Remote COVID-19 Assessment in Primary Care) study investigates the predictive risk of hospitalization, deterioration, and death of patients with confirmed COVID-19, based on a set of parameters chosen through a Delphi process performed by clinicians. We aim to use rich data collected remotely through the use of electronic data templates integrated in the electronic health systems of several general practices across the United Kingdom to construct accurate predictive models. The models will be based on preexisting conditions and monitoring data of a patient’s clinical parameters (eg, blood oxygen saturation) to make reliable predictions as to the patient’s risk of hospital admission, deterioration, and death. Objective: This statistical analysis plan outlines the statistical methods to build the prediction model to be used in the prioritization of patients in the primary care setting. The statistical analysis plan for the RECAP study includes the development and validation of the RECAP-V1 prediction model as a primary outcome. This prediction model will be adapted as a three-category risk score split into red (high risk), amber (medium risk), and green (low risk) for any patient with suspected COVID-19. The model will predict the risk of deterioration and hospitalization. Methods: After the data have been collected, we will assess the degree of missingness and use a combination of traditional data imputation using multiple imputation by chained equations, as well as more novel machine-learning approaches to impute the missing data for the final analysis. For predictive model development, we will use multiple logistic regression analyses to construct the model. We aim to recruit a minimum of 1317 patients for model development and validation. We will then externally validate the model on an independent dataset of 1400 patients. The model will also be applied for multiple different datasets to assess both its performance in different patient groups and its applicability for different methods of data collection. Results: As of May 10, 2021, we have recruited 3732 patients. A further 2088 patients have been recruited through the National Health Service Clinical Assessment Service, and approximately 5000 patients have been recruited through the DoctalyHealth platform. Conclusions: The methodology for the development of the RECAP-V1 prediction model as well as the risk score will provide clinicians with a statistically robust tool to help prioritize COVID-19 patients. Trial Registration: ClinicalTrials.gov NCT04435041; https://clinicaltrials.gov/ct2/show/NCT04435041 International Registered Report Identifier (IRRID): DERR1-10.2196/30083

3 March 2025 in Plant Science Today
Verified
Journal Article
Open access
PDF file
NPNallathambi Premalatha
Nallathambi Premalatha
AHA T Hemavathy
A T Hemavathy
KMK Mahadevan
K Mahadevan
DKD Kavithamani
D Kavithamani
SKS Kavitha
S Kavitha
SSS M Samyuktha
S M Samyuktha
Small regulatory proteins with a size range of 5 to 20 kilodaltons (kDa) are known as microproteins (miPs). They are connected to bigger, frequently multi-domain proteins and typically include a single protein domain. Through their interactions with other proteins, these microproteins modify the post-translational gene expression level. Numerous microproteins that are essential for controlling transcription factor activity have been discovered in both plants and animals in recent years. Microproteins are necessary for several phases of plant development, such as seed germination, seedling growth, stomatal regulation, root formation, pigment synthesis, blooming and floral development. Certain microproteins viz., viral protein U (Vpu) microProtein, negatively regulates the K+ ion channel TASK1 in humans, LITTLE ZIPPER proteins found in arabidopsis which regulate transcription factor and mitochondrial microprotein BRAWNI are conserved only among vertebrates are exclusive to a given species, whilst others have evolved to be conserved since they first appeared early in evolutionary history. Food security is being challenged by the cumulative consequences of climate change and unsustainable agricultural methods, which increases the need for sustainable and innovative solutions since microproteins are essential regulators of several physiological processes in plants. They are excellent candidates for creating synthetic miPs that can be employed to support plant stress resilience leading to increased productivity. Understanding the microproteins' regulatory mechanisms is a crucial step in developing microproteins into useful biotechnological tools for crop bioengineering. There is a theory that target proteins and microproteins have similar evolutionary histories. Microproteins work at the molecular level by obstructing the assembly of higher-order protein complexes. Their potential for biotechnological applications is further enhanced by their ability to function as dominant regulators in a focused and precise manner. In addition to exploring the processes of microproteins and their functional roles in plant biology, this study intends to provide the groundwork for future investigations by helping scientists identify, characterize and map these proteins.